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Abstract: The deployment of the innate immune system in humans is essential to protect us from
infection. Human cathelicidin LL-37 is a linear host defense peptide with both antimicrobial and
immune modulatory properties. Despite years of studies of numerous peptides, SK-24, corresponding
to the long hydrophobic domain (residues 9–32) in the anionic lipid-bound NMR structure of LL-37,
has not been investigated. This study reports the structure and activity of SK-24. Interestingly, SK-24
is entirely helical (~100%) in phosphate buffer (PBS), more than LL-37 (84%), GI-20 (75%), and GF-17
(33%), while RI-10 and 17BIPHE2 are essentially randomly coiled (helix%: 7–10%). These results
imply an important role for the additional N-terminal amino acids (likely E16) of SK-24 in stabilizing
the helical conformation in PBS. It is proposed herein that SK-24 contains the minimal sequence for
effective oligomerization of LL-37. Superior to LL-37 and RI-10, SK-24 shows an antimicrobial activity
spectrum comparable to the major antimicrobial peptides GF-17 and GI-20 by targeting bacterial
membranes and forming a helical conformation. Like the engineered peptide 17BIPHE2, SK-24 has a
stronger antibiofilm activity than LL-37, GI-20, and GF-17. Nevertheless, SK-24 is least hemolytic at
200 µM compared with LL-37 and its other peptides investigated herein. Combined, these results
enabled us to appreciate the elegance of the long amphipathic helix SK-24 nature deploys within
LL-37 for human antimicrobial defense. SK-24 may be a useful template of therapeutic potential.

Derived from the NMR Structure of
Human Cathelicidin LL-37.
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In insects, different antimicrobial peptides (AMPs) are induced in response to the infection of invading pathogens. In the case of Gram-positive bacteria and fungi, drosomycin,
metchnikowin, and defensin are expressed via the Toll pathway. In contrast, diptericin,
drosocin, cecropins, and attacins are expressed to combat primarily Gram-negative bacteria
via the Imd pathway [1]. Humans also deploy host defense peptides to fend off invading
pathogens [2]. Lysozyme, isolated by Alexander Fleming in 1922, is regarded as the first
antimicrobial protein [3]. It contains four pairs of disulfide bonds. Since 1985, additional
disulfide-linked AMPs, such as human α- and β-defensins, have been discovered [4,5].
Subsequent bioinformatic studies predicted two dozen of human defensins with three
characteristic disulfide bonds [6]. However, only one cathelicidin gene is predicted in
the human genome based on a highly conserved precursor region [7]. The mature region
encodes a 37-residue linear antimicrobial peptide starting with a pair of leucines, thereby
dubbed LL-37. This peptide has a net charge of +6 (six lysines, five arginines, no histidine,
three glutamic acids, and two aspartic acids) and a hydrophobic content of 35% based on
the upgraded antimicrobial peptide database (APD; https://aps.unmc.edu (accessed on
29 September 2021)) [8]. It does not contain methionine, alanine, tryptophan, histidine,
tyrosine, and cysteine. As a consequence, LL-37 is unable to form disulfide bonds. This
peptide has been detected in the saliva, skin, and lung. Sunlight and vitamin D can induce
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the expression of LL-37 [9] to combat bacteria, fungi, viruses, and parasites. Besides, this
human cathelicidin inhibits biofilm formation, suppresses the TLR-4 pathway by neutralizing bacterial lipopolysaccharides (LPS), regulates host cytokine release, and promotes
wound healing [10–15].
The broad-spectrum antimicrobial activity of LL-37 stimulated the interest in developing this molecule into peptide antibiotics to combat antibiotic-resistant pathogens.
Numerous labs attempted to identify the active regions of LL-37 [16–27]. While the Nterminal region of LL-37 is less active [24], multiple antimicrobial peptides are discovered
from the central region of LL-37 [14,15]. Braff et al. identified multiple active peptides
via a library approach [16]. A C-terminal LL-37 fragment was discovered via proteolysis [17]. We identified the major antimicrobial and anticancer region GF-17 corresponding
to residues 17–32 of LL-37 via the NMR-trim technology [18]. Another peptide, GI-20,
derived from residues 13–32, was found to have antiviral, antibacterial, and spermicidal
activities [28–31]. Based on the 3D-NMR-determined LL-37 structure bound to membrane
mimetic micelles [26], it became clear to us that a long helical region starting at residue S9
and ending before P33 of LL-37 has not been studied (Figure 1). This study investigates the
structure and activity of this long helical region. A peptide corresponding to residues 9–32
of LL-37 was synthesized and named SK-24 according to the LL-37 nomenclature. In this
convention, SK represents the first two amino acids of the new peptide, and 24 indicates
the length of the peptide. Additionally, we refer to amino acids in SK-24 based on their
positions in the parent peptide, LL-37. Thus, SK corresponds to residues 9 and 10 of
LL-37, respectively. For comparison, we also included shorter LL-37 peptides (GI-20, GF-17,
17BIPHE2, and RI-10) we obtained previously [18,26,30,32]. Our study shines light on the
region of LL-37 involved in oligomerization. Remarkably, SK-24 shows poor cytotoxicity to
human erythrocytes but potency against bacteria in planktonic and biofilm forms. Such
a combined feature for a peptide is desired in search for novel antimicrobials to combat
antibiotic-resistant pathogens.

Figure 1. (A) Identification of the SK-24 peptide based on the three-dimensional structure of human
cathelicidin LL-37 determined by 3D NMR spectroscopy (PDB ID: 2K6O) [26]. In the figure, hydrophobic amino acids are in gold and backbone in grey. Amino acids S9 and P33 are represented in
the space-filling model. (B) The amino acid sequences of LL-37 and its derived peptides. The SK-24
sequence (residues 9–32) is in gold. X represents biphenylalanines, and italic L indicates D-leucines
in 17BIPHE2. All LL-37 fragments are C-terminally amidated.
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2. Results
2.1. Peptide Design and Properties
In the membrane-bound LL-37 structure determined by 3D NMR spectroscopy, a
hydrophobic gap exists (Figure 1A). The location of a hydrophilic S9 on the hydrophobic
surface of LL-37 splits the long helix into two hydrophobic domains (gold sticks). The
SK-24 peptide we identified here corresponds to the long hydrophobic domain [26]. The
amino acid sequence of SK-24, along with LL-37 and its derived antimicrobial peptides,
is depicted in Figure 1B. Peptide parameters, including net charge, hydrophobic content,
Boman index, GRAVY, hydrophobicity, and hydrophobic moment of each peptide, were
calculated using online tools, such as the APD [8] and HeliQuest [33] (Table 1). The HPLC
retention time [34] measured for each peptide is also provided in Table 1. Except for the
shortest RI-10 (net charge +3), LL-37 and its other derived peptides have net charges +5 or
+6, above the average net charge (+3.3) of natural antimicrobial peptides registered in the
APD [8,35,36]. Overall, the hydrophobic percentages (Pho) of these peptides calculated in
the APD are proportional to the hydrophobicity and hydrophobic moment calculated by
HeliQuest in Table 1. Of note, LL-37 has the highest net charge (+6) and Boman index but
the lowest Pho%, GRAVY, and hydrophobic moment.
Table 1. Peptides, calculated parameters, and measured HPLC retention times.
Peptide a

Net
Charge

Pho%

Boman
Index

GRAVY

Hydrophobicity

Hydrophobic
Moment

tHPLC (min)

LL-37

+6

35

2.99

−0.72

0.201

0.521

12.548

SK-24

+6

37

2.95

−0.69

0.164

0.662

12.291

GI-20

+5

45

2.47

−0.23

0.329

0.729

12.681

GF-17

+5

47

2.47

−0.09

0.378

0.771

12.197

NA

NA

NA

10.753

−0.01

0.431

0.804

8.831

b

17BIPHE2

+5

47

NA

RI-10

+3

50

2.78

a

All LL-37-derived peptides, except for LL-37 itself, are C-terminally amidated. The peptide net charge, hydrophobic content (Pho%),
Boman index, and GRAVY were calculated using the antimicrobial peptide database (APD) calculation tool (https://aps.unmc.edu/
prediction (accessed on 29 September 2021)) [8]. HeliQuest (Heliquest.ipmc.cnrs.fr) was used to calculate the hydrophobicity and
hydrophobic moment [33]. HPLC retention time (tHPLC ) was measured as described [34]. b NA, not available.

2.2. Secondary Structure in Phosphate Buffer and Membrane Mimetic Micelles
LL-37 became helical upon association with membranes or their mimics based on
both circular dichroism (CD) and NMR studies [21,26,37]. To provide evidence for helix
formation, we recorded CD spectra of SK-24 as well as LL-37 and other peptides (Figure 2).
Because CD is especially suitable to follow the change in peptide conformation under
different conditions, we acquired spectra in both phosphate buffer (PBS) and the micelles
of sodium dodecyl sulfate (SDS). SDS is a widely utilized model to mimic anionic lipids
of bacterial membranes. In the case of LL-37, we observed a similar ordered–disordered
structural pattern in SDS, dioctanoyl phosphatidylglycerol (D8PG), and lipopolysaccharides (LPS). Such a structural pattern is in full agreement with the heteronuclear 15 N NOE
plot [26]. For LL-23, we found the same secondary structure in SDS, D8PG, and dodecylphosphocholine (DPC) [24]. Usually, a typical linear peptide does not have an ordered
structure in PBS, and only becomes helical after binding to membranes. We estimated
peptide helicity based on the 222 nm band. In SDS, RI-10 was much more helical (75%)
than 17BIPHE2 (25%). The poor helicity of 17BIPHE2 due to the insertion of D-amino acids
at three sites agrees with the 3D structure determined by NMR spectroscopy [18]. Other
peptides were rather different in that they were more or less helical already in PBS at the
concentration we studied (0.5 mM). In the case of LL-37 and GF-17, they became more helical in SDS micelles. Noticeably, SK-24 and GI-20, especially SK-24, were slightly less helical
in SDS (Table 2). The same conclusion could be derived based on R1 and R2 values [38].
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R1 is the molar ellipticity ratio at 192 and 206 nm, whereas R2 is the molar ellipticity ratio
at 222 and 208 nm. In complex with SDS micelles, LL-37, SK-24, GI-20, GF-17, and RI-10
displayed similar R1 and R2 values (Table 2), indicating similar helical conformations. Only
17BIPHE2 was very different as a consequence of a distorted backbone conformation as
determined by NMR [18]. In PBS, GF-17, GI-20, SK-24, and LL-37 had similar R2, although
R1 varied from −1.14 to −2.48.

Figure 2. Circular dichroism spectra of SK-24 and its related peptides in 10 mM PBS buffer and in
the presence of SDS micelles at pH 7 and 25 ◦ C. The peptides include (A) LL-37, (B) SK-24, (C) GI-20,
(D) GF-17, (E) RI-10, and (F) 17BIPHE2. The peptide concentration was fixed at 0.5 mM in all the
spectra, and the peptide/SDS molar ratio was 1:60.
Table 2. Helicity, R1, and R2 calculated from the CD spectra of LL-37 and its fragment peptides in
phosphate buffer or bound to membrane mimetic SDS micelles a .
PBS
Peptide

a

60 mM SDS

Helicity

R1

R2

Helicity

R1

R2

LL-37

83.8

−1.94

0.92

97.2

−2.08

0.91

SK-24

105.4

−1.14

0.87

67.6

−2.31

0.86

GI-20

75.1

−2.48

0.98

71.8

−2.40

0.89

GF-17

33.3

−1.91

0.85

54.3

−2.40

0.87

17BIPHE2

7.1

1.18

0.37

25.3

−3.23

1.47

RI-10

9.9

−8.95

24.27

75.5

−2.17

0.78

R1 is the molar ellipticity ratio of 192/208, while R2 is the ratio of 222/208.

2.3. SK-24 Has a Broad Antibacterial Activity
The minimal inhibitory concentrations (MICs) of SK-24 against various clinical and
antibiotic-resistant pathogens are listed in Table 3. SK-24 showed good antibacterial activity
against Enterococcus faecium, Staphylococcus aureus USA300, and Acinetobacter baumannii
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with MIC values in the range of 2–8 µM. It inhibited the growth of Escherichia coli E423-17
at 16 µM and had poor effect on Pseudomonas aeruginosa E411-17 and Klebsiella pneumoniae
E406-17 at 32 µM. For comparison, we also tested the antibacterial activity of LL-37 and its
select peptides we obtained previously. The antimicrobial spectrum of SK-24 resembled
GI-20 and GF-17. SK-24 was superior to LL-37, which displayed higher MIC values in
most of the cases even in 15% tryptic soy broth (TSB). We recently found similar MIC
values for a short lipoLL-37 peptide in 100% TSB and Mueller Hinton Broth (MHB) [39]. It
appeared that 17BIPHE2, engineered based on GF-17 [32], was most potent in killing these
pathogens with MIC in the range of 2–8 µM. Consistent with our previous finding [26],
RI-10 did not show any inhibitory activity at 32 µM (Table 3). The loss of the antimicrobial
activity of RI-10 may be explained by the shortest HPLC retention time, indicative of a least
hydrophobic peptide in Table 1.
Table 3. Bacterial minimal inhibitory concentration (µM) of LL-37 and its derived peptides against drug-resistant pathogens a .
MIC (µM)
Bacterial Strain

LL-37

SK-24

GI-20

GI-20d

GF-17

17BIPHE2

RI-10

E. faecium V284-17

32

2

2

1

2

2

>32

S. aureus USA300

≥32

4

2–4

2

2–4

4

>32

K. pneumoniae
E406-17

16–32

≥32

>32

>32

>32

4–8

>32

A. baumannii B28-16

8

4–8

8

4

4

4–8

>32

P. aeruginosa E411-17

>32

>32

>32

32

16

8

>32

E. coli E423-17

>32

16

32

32

16

4

>32

a Activity

evaluated in 100% TSB.

2.4. Antibiofilm Activity of SK-24
To further gauge peptide activity, we then compared the antibiofilm activity of SK-24
in disrupting the preformed biofilms of Gram-negative A. baumannii B28-16 and Grampositive S. aureus USA300 LAC. Again, LL-37 and its selected peptides were included for
comparison. The biofilms of A. baumannii were formed for 24 h (Figure S1), 48 h (Figure 3),
and 72 h (Figure 4), respectively. In all the cases, LL-37 and RI-10 treated at 8, 16, 32, or
64 µM were unable to disrupt the preformed biofilms of A. baumannii. However, SK-24,
as well as GF-17, GI-20, and 17BIPHE2, all reduced biofilms established in 24 h in a dosedependent manner (Figure S1). Here, the biofilm-elimination ability of SK-24 appeared
to be comparable to that of GI-20 and GF-17 but was slightly less effective than that of
17BIPHE2. For the 48 h biofilms, we also observed dose-dependent biofilm disruption for
SK-24, GF-17, and 17BIPHE2, although GI-20 became less potent (Figure 3) and only worked
at 64 µM. In the case of the 72 h preformed biofilms, we only observed a clear biofilm
decrease in SK-24, GF-17, GI-20, and 17BIPHE2 at 64 µM, the highest concentration tested
(Figure 4). SK-24 and 17BIPHE2 appeared to be slightly more effective (~70% disruption)
than GF-17 or GI-20 (30–50% disruption).
In the case of Gram-positive bacteria, we found previously that neither LL-37 nor
RI-10 was able to disrupt the 24 h preformed biofilms of S. aureus USA300 LAC as well as
other clinical strains, including S. aureus USA200, S. aureus USA400, and S. aureus Mu50.
However, both GF-17 and 17BIPHE2 were highly effective [25]. Here, we compared the
antibiofilm activity of SK-24 with that of GF-17, GI-20, and 17BIPHE2 against the 24 h
preformed biofilms of S. aureus USA300. SK-24, similar to GF-17, GI-20, and 17BIPHE2,
showed an antibiofilm effect in a dose-dependent manner (Figure S2). Only SK-24 and
17BIPHE2 reduced the Staphylococcal biofilms to ~25% at 32 µM.
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Figure 3. Antibiofilm activity of SK-24 and LL-37 peptides against A. baumannii B28-16: (A) LL-37,
(B) SK-24, (C) GI-20, (D) GF-17, (E) 17BIPHE2, and (F) RI-10. Biofilms were established for 48 h.

Figure 4. Antibiofilm activity of SK-24 and LL-37 peptides against A. baumannii B28-16: (A) LL-37,
(B) SK-24, (C) GI-20, (D) GF-17, (E) 17BIPHE2, and (F) RI-10. Biofilms were established for 72 h.

2.5. SK-24 Targets Bacterial Membranes
SK-24 corresponds to the long central helix of LL-37 (Figure 1). It is reasonable to
predict that the new peptide also acts on bacterial membranes like its parent peptide LL37. To validate this, we conducted membrane permeabilization as well as depolarization
experiments. Both Gram-positive S. aureus USA300 and Gram-negative A. baumannii B28-16
were utilized in the membrane permeation experiment (Figure 5), where a nonmembrane
permeable dye, propidium iodide (PI), was used as an indicator. Peptides were treated at
different levels, and the same trend was observed. At 8 µM, SK-24 weakly permeated the
S. aureus membranes (Figure 5A). It was slightly better than LL-37 and RI-10 in damaging
S. aureus. In the same experiment, however, 17BIPHE2 and GI-20 were more powerful.
We also followed the membrane permeation of A. baumannii (Figure 5B). At 16 µM, SK-24
was similar to human LL-37 and its major antibacterial peptide GF-17. Again, GI-20 and
17BIPHE2 were superior to SK-24. Thus, there is a consensus that GI-20 and 17BIPHE2 are
more potent than GF-17 and SK-24 in permeating the membranes of both Gram-positive
and Gram-negative bacteria. Notably, RI-10 also showed some membrane permeation of
both S. aureus (Figure 5A) and A. baumannii (Figure 5B), although it failed to inhibit the
growth of these bacteria at 32 µM (Table 3).
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Figure 5. Membrane permeabilization of (A) S. aureus USA300 LAC treated at 8 µM and (B) A. baumannii treated at 16 µM of SK-24 and LL-37 peptides based on a change in the fluorescence of the dye
propidium iodide.

In the membrane depolarization experiment, SK-24 induced membrane depolarization
in a dose-dependent manner (Figure 6). At 8 µM (panel B), it was stronger than LL-37
in polarizing the membranes of S. aureus USA300. Like membrane permeation, GI-20
and 17BIPHE2 showed a stronger membrane depolarization ability in the following order:
GI-20 > 17BIPHE2 > GF-17~SK-24 > LL-37. RI-10, which is not inhibitory to bacterial
growth, was unable to produce a similar effect on bacterial membranes. Similar trends
were retained at higher peptide concentrations of 16 and 32 µM (panels C and D). Hence,
both experiments underscored the effect of SK-24 on bacterial membranes.

Figure 6. Effects of SK-24 and LL-37 peptides on membrane depolarization of the mid-log phase
S. aureus USA300 LAC resuspended in PBS and energized with glucose for 15 min at 37 ◦ C treated
at a peptide concentration of 4 µM (A), 8 µM (B), 16 µM (C), and 32 µM (D) post-20 min dye
equilibration. The detergent Triton X-100 (TrtnX, 0.1%) at a constant concentration was included as a
positive control.

2.6. Hemolytic Ability of SK-24
Using the established lab protocol [40], we also compared the hemolytic activity of
SK-24 with LL-37 and its peptides. RI-10 is least hemolytic, consistent with the least hydrophobicity based on the HPLC retention time (Table 1). Similar to RI-10, SK-24 displayed
minimal hemolysis (<25%) even at 200 µM (Figure 7), indicating a 50% hemolytic concentration (HC50 ) greater than 200 µM. This appears to correspond to its lowest calculated
hydrophobicity in Table 1. LL-37 showed no hemolysis below 100 µM. At 200 µM, however,
it became rather hemolytic (70% hemolysis) with an HC50 of ~175 µM. Like LL-37, GF-17
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showed an abrupt increase in hemolysis at 100 µM (HC50 ~175 µM). GI-20, with an HC50
of ~160 µM, appeared to be slightly more hemolytic than GF-17. As a positive control, the
engineered peptide 17BIPHE2 is poorly hemolytic with an HC50 of ~200 µM, consistent
with our previous finding, although the absolute lysis percentages differ due to a difference
in blood cell batches [32].

Figure 7. Hemolytic toxicity of SK-24 in comparison with LL-37, GF-17, GI-20, RI-10, and 17BIPHE2.
The percentages of human red blood cell lysis were calculated relative to the untreated control and
plotted versus the peptide concentration in the range of 12.5–200 µM.

3. Discussion
Human cathelicidin LL-37 is one of the best-studied antimicrobial peptides with
antimicrobial and immune regulatory functions [10–15]. It is able to inhibit both Grampositive and Gram-negative bacteria via membrane targeting. At low concentrations,
especially acidic pHs, LL-37 does not have an ordered structure [11,21]. Such a randomly
coiled state is frequently used as a starting point for LL-37 to attach bacterial membranes via
initial electrostatic interactions where R23 is a critical cationic residue [26,41]. Subsequently,
residues 2–31 of LL-37 become helical due to association with the outer-membrane LPS
of Gram-negative bacteria or after binding to anionic phosphatidylglycerols (PGs) of
bacteria membranes according to isotope-labeled heteronuclear NMR studies [26]. The
carpet model [42] describes this state when LL-37 sits on the surface of the membranes.
The toroidal pore model suggests a pore formation where both LL-37 and lipids can be
located in the interface [43,44]. With an increase in peptide concentration, the peptide
even lyses bacterial membranes into small pieces, forming a totally different phase of
peptide–membrane complexes [45].
The membrane targeting of LL-37 can be more complex since the peptide might
have already been a helix at an elevated concentration in PBS, as observed previously by
others [21] and here by us (Figure 2). Size-exclusion chromatography estimated a tetramer
formation. Based on NMR data, we proposed the involvement of nearly the entire LL-37
(residues 1–36) in oligomerization [11]. Here, we gained additional insight into LL-37
oligomerization by comparing a series of LL-37 fragments. Previous studies established
that LL-37 became helical in PBS due to oligomerization [21]. It is interesting to note that
GF-17 at 0.5 mM is less helical in PBS than either GI-20 or SK-24. It is logical to reason that
those N-terminal residues absent in GF-17 are required for helix formation probably via
oligomerization. Possibly, E16 is a key residue, which is absent in GF-17, but present in
GI-20, SK-24, and LL-37. Interestingly, in a dimeric crystal structure of LL-37, E16 forms
hydrogen bonds with S9 in the dimer interface [46], providing one possible role for this
acidic residue in LL-37 oligomerization. We may apply such an interaction to the LL-37
peptides investigated here to explain the different degrees of helicity in PBS. Both S9 and
E16 exist in SK-24, allowing for similar S9–E16 interactions between different chains of
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LL-37 in the oligomer, leading to a longer helix in PBS. Since S9 is absent in GI-20, this
peptide is less helical than SK-24 in PBS. In GF-17, the lack of both S9 and E16 would
explain the low helicity in PBS (Table 2).
Shai found that oligomers of LL-37 were retained in zwitterionic lipids but were
dissociated into monomer in anionic lipids [22]. We found here that LL-37 became more
helical in association with SDS micelles than in PBS. Likewise, GF-17 was more helical in
membranes. However, GI-20 was slightly less helical in complex with SDS micelles. A less
helical structure bound to SDS than in PBS is even more pronounced for SK-24 (Table 2).
Such a decrease in helicity may result from electrostatic repulsions between the anionic
headgroup of SDS and acidic amino acids in GI-20 (E16) and SK-24 (E11 and E16) (Figure 1).
Our speculation agrees with 3D structures determined for GF-17 and GI-20 bound to SDS
micelles. While GF-17 is entirely helical [47], the N-terminus of GI-20 is not. Interestingly,
GI-20 is entirely helical bound to DPC or D8PG, indicating a lack of such repulsions with
zwitterionic DPC or a weaker repulsion with D8PG [41,48]. Such an electrostatic repulsion
might have been overcome in the case of full-length LL-37 due to the association of the
N-terminal hydrophobic region (LLGDFF) of LL-37 with anionic micelles. Thus, LL-37
retains a long helix after association with either SDS or D8PG micelles [26].
Peptide length also plays an important role in determining peptide activity. The
smallest antibacterial peptide KR-12 is active against E. coli but not S. aureus [26]. RI-10,
obtained by further truncation of KR-12, loses its antimicrobial activity (Figure 1). FK-13
is the minimal anti-HIV peptide, indicating the significance of the N-terminal aromatic
phenylalanine [30]. Further extension of FK-13 by three residues NLV at the C-terminus
leads to GF-17 (G is also appended to the N-terminus to mimic some natural AMPs),
which is the major antimicrobial peptide with a broad-spectrum activity against both E.
coli and S. aureus [47]. During our study of the sequence–activity relationship of antiHIV peptides, GI-20 was found to have a higher therapeutic index than GF-17 [30]. This
study addresses the important question of whether SK-24, a helical peptide longer than
GF-17 and GI-20 of LL-37, has any advantages in killing bacteria in the planktonic and
biofilm forms. Our results indicate an antibacterial activity spectrum of SK-24 similar
to GF-17 and GI-20 in the case of planktonic bacteria (Table 3), indicating that the extra
residues in SK-24 (Figure 1) did not contribute substantially to MIC values. This is logical
considering that the LL-37 peptides target bacterial membranes, and additional residues at
the N-terminal region of SK-24 are either polar or charged. LL-37 is also reported to inhibit
biofilm formation under a low peptide concentration [25,49]. However, LL-37, as well as
the inactive peptide RI-10, is not effective in disrupting the preformed biofilms of MRSA,
whereas the major antimicrobial peptide GF-17 and its engineered peptide 17BIPHE2
are much more effective [25]. 17BIPHE2 also inhibits P. aeruginosa adhesion and biofilm
formation. In the more challenging case of preformed biofilms, it works even better in
the presence of antibiotics [50]. In this study, the longer peptide, SK-24, is found to be
more effective in disrupting preformed biofilms of A. baumannii and S. aureus than GI-20
and GF-17. Interestingly, only SK-24 shows an antibiofilm activity against the 72 h biofilm
of A. baumannii comparable to the engineered peptide 17BIPHE2 at an elevated peptide
concentration (Figure 4). Kanthawong et al. found that LL-31, corresponding to the entire
helical region in the membrane-bound NMR structure of human LL-37 (Figure 1) [26], is
potent against biofilms [51]. A recently reported antibiofilm peptide, SAAP-148, optimized
based on a long LL-37 fragment, IG-24 (a C-terminally extended version of GI-20) (reviewed
in [15]), is also a long peptide with 24 amino acids [52]. Collectively, these results would
suggest that longer LL-37 peptides have antibiofilm advantages.
SK-24 has one more advantage. Our toxicity analysis indicates that, among the peptides derived from the long helix of LL-37 (Figure 1), SK-24, similar to RI-10, is least
hemolytic (Figure 7). A possible reason is that the SK-24 peptide has a low hydrophobic content (37%), resembling the parent peptide LL-37 (35%), while GI-20, GF-17, and
17BIPHE2 all have a higher hydrophobic content in the range of 45-47% (Table 1). The poor
hemolysis of RI-10 may be attributed to its short sequence length, since its hydrophobic
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content and hydrophobicity are not lower than those of GF-17, GI-20, and 17BIPHE2.
In summary, our structure-based design enabled us to identify a unique peptide, which
is potent in microbial killing at low micromolar concentrations, which is unlikely to be
toxic to host cells. In addition, SK-24, corresponding to the long helical domain of LL-37
sandwiched between S9 and P32 (Figure 1), appears to contain the minimal sequence for
effective oligomerization in PBS. Future high-resolution structural studies of the SK-24
model peptide in PBS may unveil the molecular mechanism of its oligomerization.
4. Materials and Methods
4.1. Peptides and Chemicals
All peptides were chemically synthesized and purified to >95% (Genemed Synthesis, San Antonio, TX, USA). The quality of each peptide was determined based on mass
spectrometry (MS) and high-performance liquid chromatography (HPLC). Peptide stock
solutions were freshly made by solubilizing in autoclaved distilled water, and their concentrations were quantitated using UV spectroscopy based on the absorbance difference at
215 and 225 nm as described [18]. Peptide retention time was measured on a Waters C8
symmetry hydrophobic column as described [34]. Other chemicals were purchased from
Sigma (St. Louis, MO, USA) unless specified.
4.2. Circular Dichroism (CD)
CD spectra were measured on a Jasco J-815 spectropolarimeter in the far-UV region
from 260 to 190 nm with a 1 nm interval, a 2 nm bandwidth using a digital integration
time of 4 s, and a scan speed of 20 nm per min. During measurement, the high-tension
signal applied to the detector was also recorded and was subsequently converted to
absorbance. Data represent the average of five individual scans with a corresponding
reference measurement on pure solvent subtracted [21,39]. The peptide concentration was
fixed at 0.5 mM in 10 mM PBS (pH 7) with or without 60 mM of sodium dodecyl sulfate
(SDS). Each sample solution was placed in a 0.1 mm quartz cuvette. The temperature was
kept at 25 ◦ C during measurements. Data were processed and converted to molar ellipticity
[θ] using the Jasco Spectra Analysis software and plotted using GraphPad Prism 7.
4.3. Antibacterial Assays
The antibiotic-resistant pathogens used in this study include the Gram-positive bacteria Enterococcus faecium V286-17 and Staphylococcus aureus USA300 LAC and the Gramnegative bacteria Klebsiella pneumoniae E406-17, Acinetobacter baumannii B28-16, Pseudomonas
aeruginosa E411-17, and Escherichia coli E423-17. All bacteria were cultivated in tryptic soy
broth (TSB) at 37 ◦ C, 220 rpm.
The antibacterial activity of peptides was evaluated using a standard broth microdilution protocol [53] with minor modifications [40]. In brief, peptides were made at various
concentrations, 10 µL per well in a 96-well polystyrene microplate. Logarithmic phase
bacterial cultures (i.e., optical density (OD) at 600 nm ≈ 0.5) were diluted to 0.001 OD, and
aliquots of 90 µL were added to each well. Untreated bacterial culture and medium were
included as positive and negative controls, respectively. Plates were incubated at 37 ◦ C
overnight and read at 630 nm using a ChroMate Microplate Reader (Awareness Technology,
Palm City, FL, USA). The MIC is the lowest peptide concentration that completely inhibits
bacterial growth. Our previously designed peptide 17BIPHE2 [32] was included as a
positive control, and RI-10, a peptide without antibacterial activity in rich media [26], was
utilized as a negative control.
4.4. Antibiofilm Assays
The antibiofilm activities of peptides against the preformed biofilms of A. baumannii
B28-16 and S. aureus USA300 LAC were evaluated as follows. Bacteria in the logarithmic
growth phase were adjusted to a cell density of 105 colony forming unit (CFU)/mL. Two
hundred microliter cells were seeded into each well of the 96-well plates. The plates were
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incubated at 37 ◦ C to allow for the formation of biofilm for 24, 48, and 72 h, respectively.
The planktonic cells were then removed, followed by a wash. The biofilms were then
treated with 20 µL of 10× two-fold diluted peptides and 180 µL of fresh TSB media
for 24 h at 37 ◦ C. Cultures treated with water without peptide served as the positive
control, and media treated with water was used as the negative control. To quantify the
antibiofilm activity of the peptides, the XTT [2, 3-bis (2-methyloxy-4-nitro-5-sulfophenyl)2H-tertazolium-5-carboxanilide] assay staining method was used to quantitate the live
cells [54–56]. Absorbance was read at 450 nm using a ChroMate microliter plate reader. The
percentage biofilm growth for the peptide was plotted by assuming 100% biofilm growth
in untreated bacterial control wells. Data were represented as mean ± standard deviation
(SD). The data are statistically significant at p < 0.05. Plots were generated using GraphPad
Prism v7 (GraphPad Software, San Diego, CA, USA).
4.5. Membrane Permeabilization
Membrane permeabilization was evaluated as described [39]. In brief, bacteria were
inoculated and grown overnight. A second inoculation was made and let bacteria grow
to the exponential phase. Bacteria were then spun, washed, and resuspended in the same
volume of PBS. A series of peptide solutions (10×) was made via two-fold dilution in a
96-well plate (10 µL each). All wells were aliquoted with 2 µL of propidium iodide (20 µM),
followed by adding 88 µL of S. aureus USA300 or A. baumannii B28-16 (OD600 ~0.11 in PBS).
The plate was incubated at 37 ◦ C with continuous shaking at 100 rpm in a FLUOstar Omega
microplate reader (BMG Labtech Inc., Cary, NC, USA). Fluorescence was recorded every
5 min for 2 h with excitation and emission wavelengths of 485 and 620 nm. The data were
analyzed by the vendor’s software using averaged values from duplicated experiments.
4.6. Membrane Depolarization of Bacteria
The experiment was conducted as described [39]. In brief, an overnight culture
of S. aureus USA300 LAC was subcultured in a fresh TSB medium and grown to the
exponential phase. Cells were spun using centrifugation and washed twice with PBS, and
resuspended in twice the volume of PBS containing 25 mM glucose and incubated at 37 ◦ C
for 15 min. For membrane depolarization measurements, 500 nM (final concentration) of
the dye DiBAC4 (3) (bis-(1,3- dibutylbarbituric acid) trimethine oxonol) (AnaSpec, San Jose,
CA, USA) was added and vortexed gently. Aliquots of 90 µL of the energized bacteria
solution were loaded to the wells, and the plate was fed into a FLUOstar Omega microplate
reader. Fluorescence was read for 20 min at excitation and emission wavelengths of 485
and 520 nm, respectively, to get dye normalization. Then 10 µL of diluted peptide solutions
were added and gently mixed. Fluorescence readings were recorded for 40 min, where
Triton X-100 (0.1%) was used as a positive control.
4.7. Hemolytic Assays
Human red blood cells (hRBCs, the UNMC Blood Bank) were washed three to five
times with saline (Fisher Scientific, Waltham, MA, USA) at 800 g for 10 min each time,
until the supernatant was clear [34]. The supernatant was discarded, and hRBCs were
suspended in saline at a final density of 2%. Ninety microliters of hRBC suspensions were
added to each well of 96-well plates containing 10 µL of 10× serially diluted peptides.
After incubation at 37 ◦ C for 1 h, the plates were centrifuged at 1500 rpm for 5 min. About
80 µL of the supernatant was carefully pipetted to a new 96-well microplate and read at
545 nm to measure the amount of hemoglobin released. The positive control was 1% Triton
X-100, and the negative control was saline. The percentage of hRBC lysis was calculated
based on the hemoglobin released.
5. Conclusions
Although there are over 3000 natural antimicrobial peptides in the antimicrobial
peptide database, human cathelicidin LL-37 is one of the best characterized antimicrobial
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peptides discovered to date. Both a library approach and a structure-based design have
been utilized to identify active peptides from human cathelicidin LL-37 (reviewed in [15]).
Based on the 3D structure of LL-37 [26], we identified the minimal antibacterial peptide
KR-12 and minimal antiviral peptide FK-13. In addition, GF-17 is the major antimicrobial
and anticancer peptide. Here, we identified SK-24 through a detailed analysis of the 3DNMR-determined structure of LL-37 bound to membranes (Figure 1). It appears that SK-24
contains the minimal sequence for effective oligomerization of LL-37. Perhaps nature has
designed the SK-24 peptide elegantly so that it possesses a stronger antibiofilm ability, but
lower toxicity, than its shorter antimicrobial peptides, GI-20 and GF-17, opening the door
to potential therapeutic use.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/ph14121245/s1, Figure S1: Effects of LL-37 peptides on the 24 h-formed biofilms of A. baumannii
and Figure S2: Effects of LL-37 peptides on the 24 h-formed biofilms of S. aureus.
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